“ADC新星”上市首日大涨超100%,市值突破170亿港元

国际金融报
16 Apr

4月15日,生物医药行业备受瞩目的抗体偶联药物(ADC)新星映恩生物终于正式亮相资本市场,于港交所主板挂牌上市,股票代码HK9606.  截至收盘,公司股价报收205港元/股,大涨116.7%,总市值突破170亿港元。  另据发售公告,映恩生物本次香港公开发售获115.14倍的超额认购,国际配售获13.52倍认购,最终发售价为每股94.6港元,全球发售净筹约15.13亿港元。  这也刷新了港股...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10